Information Provided By:
Fly News Breaks for November 23, 2016
PCRX
Nov 23, 2016 | 11:13 EDT
According to Symphony data released today, October sales of Pacira Pharmaceuticals' Exparel were $20.2M, down 12% year-over-year and down 9% month-over-month, BMO Capital analyst Gary Nachman tells investors in a research note. The analyst views the number as "not a great start" to Q4 and thinks Pacira may be challenged to hit the low end of its $263M-$268M Exparel sales guidance. He keeps a Market Perform rating on the shares with a $35 price target. Pacira is down 8%, or $2.75, to $31.60 in late morning trading.
News For PCRX From the Last 2 Days
There are no results for your query PCRX